fbpx
Request Support
Request Info
Resources|Resource Type|Case Studies|Xstrahl in Action: Xstrahl 300 Used to Treat NMSC with Hypofractionated Radiotherapy

Xstrahl in Action: Xstrahl 300 Used to Treat NMSC with Hypofractionated Radiotherapy

January 26, 2021

This study, Hypofractionated Radiotherapy in Older Patients with Non-melanoma Skin Cancer: Less is Better, explores how our Xstrahl 300 system was used to successfully treat NMSC for 3 older patients. See the full study here, and more details below.

Contact Us

Find out more about how Xstrahl will work tirelessly for you

Contact Us

Explore Related Posts

XBeam from Xstrahl Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance for Use in the U.S.

XBeam from Xstrahl Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance for Use in the U.S.

Xstrahl’s XBeam has received FDA 510(k) Clearance for Use in the U.S. The XBeam technology streamlines radiotherapy treatment planning and simplifies patient workflow for treating skin cancer, benign diseases, and palliative care. Explore how this innovation enhances orthovoltage superficial radiotherapy (SRT) and electronic brachytherapy (eBt). With XBeam, you can calculate, protocol and export treatment plans for Xstrahl treatments with Radiant Aura and all other Xstrahl medical devices in the U.S. and worldwide.

read more